Zhongguo shi yan xue ye xue za zhi · 2026
[Daporinad Potently Induces Cell Death in Ph+ Acute Lymphoblastic Leukemia SUP-B15 Cells Independent of the Intrinsic Apoptotic Pathway].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xi Jing-Jing, Wang Cong-Yue, Zhan Jia-Min, Yu Wen-Jie, Cao Xu, Yu Ao-Yang, Xu Kai-Lin, Chen Chong
Аннотация
OBJECTIVE: To investigate whether daporinad (APO866), a nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, can potently kill Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) cells via an intrinsic apoptosis-independent pathway.
METHODS: Ph+ ALL SUP-B15 cells were treated with varying concentrations of APO866. After treatment, cell viability was measured via Deep Blue assay, while apoptosis and cell death were determined by Annexin V/7-AAD double staining. Cleavage of Caspase-3 and PARP1 was detected by Western blot, and rescue experiments with the pan-caspase inhibitor Z-VAD-FMK were performed to rule out apoptotic involvement. To determine whether APO866-induced cell killing depends on nicotinamide adenine dinucleotide (NAD+) depletion, the NAD+ precursor nicotinic acid (NA) was supplemented and NAD+consuming enzyme CD38 was knocked down. Furthermore, TP53 knockout and BAX/BAK double-knockout SUP-B15 cell models were used to verify that the cytotoxic effect of APO866 is independent of the intrinsic apoptotic pathway.
RESULTS: Both Deep Blue and Annexin V/7-AAD staining assays showed that APO866 effectively kills SUP-B15 cells. This cytotoxic effect could not be abrogated by the pan-caspase inhibitor Z-VAD-FMK, and no cleavage of Caspase-3 and PARP1 was detected during the process of cell killing. Intracellular NAD+ levels were markedly decreased following APO866 treatment, and supplementation with NA or knockout of CD38 partially reversed such cytotoxicity. Neither TP53 knockout nor BAX/BAK double knockout impaired the killing efficiency of APO866 against SUP-B15 cells.
CONCLUSION: APO866 could potently induce SUP-B15 cell death by depleting intracellular NAD+ levels, a process that lacks canonical features of the intrinsic apoptotic pathway. Moreover, its cytotoxicity persists even with deficiencies in key regulators of this pathway, indicating a mechanism of action that is independent of intrinsic apoptosis.
METHODS: Ph+ ALL SUP-B15 cells were treated with varying concentrations of APO866. After treatment, cell viability was measured via Deep Blue assay, while apoptosis and cell death were determined by Annexin V/7-AAD double staining. Cleavage of Caspase-3 and PARP1 was detected by Western blot, and rescue experiments with the pan-caspase inhibitor Z-VAD-FMK were performed to rule out apoptotic involvement. To determine whether APO866-induced cell killing depends on nicotinamide adenine dinucleotide (NAD+) depletion, the NAD+ precursor nicotinic acid (NA) was supplemented and NAD+consuming enzyme CD38 was knocked down. Furthermore, TP53 knockout and BAX/BAK double-knockout SUP-B15 cell models were used to verify that the cytotoxic effect of APO866 is independent of the intrinsic apoptotic pathway.
RESULTS: Both Deep Blue and Annexin V/7-AAD staining assays showed that APO866 effectively kills SUP-B15 cells. This cytotoxic effect could not be abrogated by the pan-caspase inhibitor Z-VAD-FMK, and no cleavage of Caspase-3 and PARP1 was detected during the process of cell killing. Intracellular NAD+ levels were markedly decreased following APO866 treatment, and supplementation with NA or knockout of CD38 partially reversed such cytotoxicity. Neither TP53 knockout nor BAX/BAK double knockout impaired the killing efficiency of APO866 against SUP-B15 cells.
CONCLUSION: APO866 could potently induce SUP-B15 cell death by depleting intracellular NAD+ levels, a process that lacks canonical features of the intrinsic apoptotic pathway. Moreover, its cytotoxicity persists even with deficiencies in key regulators of this pathway, indicating a mechanism of action that is independent of intrinsic apoptosis.